Liver Failure, Acute Clinical Trial
Official title:
Efficacy of L-ornithine L-aspartate and Therapeutic Plasma Exchange Versus Plasma Exchange Alone in Lowering Ammonia and Improving Outcomes in Pediatric Acute Liver Failure: A Randomized Controlled Trial
Pediatric acute liver failure (PALF) is associated with very high mortality and morbidity with native liver survival varying between 21 to 75%.Hyperammonemia manifesting as hepatic encephalopathy and causing cerebral edema isresponsible for poor neurological outcome in ALF. Ammonia lowering measures have led to improvement in HE and higher native liver survival. L-ornithine L-aspartate (LOLA), a salt of natural amino-acids ornithine and aspartate, is an importantammonia scavenging drug. It acts as a substrate for urea cycle in liver and also converts ammonia to glutamine in perivenous hepatocytes as well as in the muscles.This drug has been shown to reduce ammonia and improve hepatic encephalopathy in cirrhoticadults.However, the issue with this drug is that the glutamine formed can reconvert to ammonia by the action of glutaminase, possibly, the reason why it failed to show decrease in ammonia and improvement in native liver survival in a randomized controlled trial in adult ALF. In western countries, ornithine phenylacetate has been used where ornithine converts ammonia to glutamine and phenylacetate then binds to this glutamine to form phenylacetylgutamine and eliminates it. Therapeutic plasma exchange (TPE), both high volume and standard volume has been shown to improve native liver survival in adults with ALF and is the standard of care in management of ALF and a grade 1 recommendation by all eminent liver societies.TPE leads to decreased ammonia. Although rate of ammonia formation is multiple times higher than rate of ammonia removal by plasmapheresis, this ammonia reduction is an indirect effect of glutamine removal by TPE. Glutamine, thus, acts as a reservoir for clearance of ammonia (in muscles and perivenous hepatocytes).In contrast to adults, the response to therapeutic plasma exchange has not been as encouraging inchildren, yet, most centers continue to use it based on recommendations in adults. Based on the knowledge that LOLA converts ammonia to glutamine and TPE clears glutamine from plasma, the investigators hypothesize that LOLA would act in synergestic way with TPE to lower ammonia levels, resulting in improvement in HE and better native liver survival in pediatric ALF. The goal of this clinical trial is to compare L-ornithine L-aspartate and therapeutic plasma exchange versus plasma exchange alone in lowering ammonia and improving outcomes in patients with pediatric acute liver failure.
Status | Not yet recruiting |
Enrollment | 32 |
Est. completion date | October 30, 2024 |
Est. primary completion date | October 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 18 Years |
Eligibility | Inclusion Criteria: - Pediatric Acute Liver Failure as defined by PALF-Study Group - 5-18 years of age - INR > 2 - Hepatic encephalopathy (defined by West Haven criteria) - Ammonia >100mcg/dL Exclusion Criteria: - Irreversible neurological injury - Previous treatment with LOLA within 48 hours before admission. - Acute kidney injury. - Acute on chronic liver failure - Those not giving consent |
Country | Name | City | State |
---|---|---|---|
India | Institute of Liver and Biliary Sciences | New Delhi |
Lead Sponsor | Collaborator |
---|---|
Institute of Liver and Biliary Sciences, India |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of change in ammonia (baseline to day 3) in the 2 groups | 72 hours | ||
Secondary | Comparison of proportion of participants dying by Day 7 and Day 14 between two groups | Days 7 and 14 | ||
Secondary | Comparison of proportion of participants requiring liver transplant by Day 7 and Day 14 between two groups | Day 7 and Day 14 | ||
Secondary | Comparison of overall survival at Day 7 and Day 14 between two groups | Days 7 and 14 | ||
Secondary | Comparison of change in grade of encephalopathy assessed by West Haven scale by day 3 and day 7 | Day 3 and Day 7 | ||
Secondary | Comparison of optic nerve sheath diameter measured by ultrasound at 24,48 and 72 hours in the 2 groups | 24 hours, 48 hours and 72 hours | ||
Secondary | To compare the cumulative requirement of mannitol and propofol in the first 72 hours in the 2 groups | 72 hours | ||
Secondary | Comparison of plasma and dialysate glutamine levels after first cycle of High Volume Plasma Exchange between two groups | 72 hours | ||
Secondary | Comparison of number of episodes of clinically raised intracranial pressure in the 2 groups | 72 hours | ||
Secondary | Compare the adverse events in the 2 groups | 72 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00225901 -
Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT01318525 -
Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure
|
Phase 2 | |
Completed |
NCT03312036 -
HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification
|
N/A | |
Not yet recruiting |
NCT03084198 -
Safety and Efficacy of hiHep Bioartificial Liver Support System to Treat Acute Liver Failure
|
N/A | |
Recruiting |
NCT01341951 -
Granulocyte Colony Stimulating Factor (G-CSF) in Acute Liver Failure and Alcoholic Hepatitis
|
N/A | |
Not yet recruiting |
NCT05473403 -
Validation of a Prognostic Score for Steroid Therapy Response in Acute Severe Autoimmune Hepatitis
|
N/A | |
Completed |
NCT04959110 -
Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT
|
N/A | |
Enrolling by invitation |
NCT01471262 -
Right Hepatectomy in Patients Beyond 70 Years Old
|
N/A | |
Recruiting |
NCT06263114 -
Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients
|
||
Completed |
NCT04512014 -
Perioperative Lactate Kinetics in Patient Undergoing Major Liver Surgery
|
||
Completed |
NCT02687763 -
Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant
|
Early Phase 1 | |
Completed |
NCT02310542 -
Comparison of Two Liver Dialysis Systems : MARS Versus SPAD in Severe Liver Failure
|
N/A | |
Completed |
NCT01394497 -
Use of N-Acetylcysteine During Liver Procurement
|
Phase 2 | |
Completed |
NCT01878305 -
Neuromonitoring of Hepatic Encephalopathy
|
N/A | |
Not yet recruiting |
NCT05817994 -
Endoscopic Ultrasound Guided Liver Biopsy and Portal Pressure Registry
|
||
Withdrawn |
NCT01137591 -
Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever
|
N/A |